Press Releases Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Real-time Estimate Cboe BZX Other stock markets 03:44:59 2024-04-29 pm EDT			5-day change	1st Jan Change
5.365 ^USD	+6.66%		+7.40%	-14.08%

Apr. 01	Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	MT
Apr. 01	HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	Apr. 24	AQ
Affimed Reports 2023 Financial Results and Operational Progress	Mar. 28	AQ
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	Mar. 21	AQ
Affimed N : Form 6-K	Mar. 11	PU
Affimed Announces 1-for-10 Reverse Stock Split	Mar. 06	AQ
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	Jan. 09	AQ
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	Jan. 08	GL
Affimed Announces Leadership Change and Organizational Restructuring	Jan. 08	AQ
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	Jan. 03	AQ
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS	Dec. 12	AQ
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	Dec. 11	GL
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)	Dec. 11	GL
AFFIMED TO HOST INVESTOR CONFERENCE CALL HIGHLIGHTING CLINICAL DATA FOR ACIMTAMIG AND AFM24	Dec. 05	AQ
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24	Dec. 04	AQ
Affimed N : Form 6-K	Nov. 30	PU
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress	Nov. 14	AQ
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13	Nov. 09	AQ
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023	Nov. 07	AQ
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	Nov. 03	GL
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	Nov. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Press Releases

Filters